drugset / Trial / NCT03945799
A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence
Phase 1/2
Terminated
28 enrolled
Zhejiang University
Huashan Hospital · collabShanghai General Hospital, Shanghai Jiao Tong University School of Medicine · collabShulan (Hangzhou) Hospital · collabThe First Affiliated Hospital of Zhengzhou University · collabThe First Hospital of Jilin University · collabThird Affiliated Hospital, Sun Yat-Sen University · collabTianjin First Central Hospital · collabWest China Hospital · collab
NaSingle-groupOpen-labelPrevention
Summary
To assess the primary effects and safety of Anlotinib in HCC patients at high risk of post surgery recurrence.
Timeline
- Start
- 2019-04-22
- Primary completion
- 2022-06-25
- Completion
- 2022-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |